Some site functionality may be unavailable due to site maintenance from 01:00 until 09:00 Sunday 21st April. We apologise for any inconvenience caused.

Csl focused on creating medical breakthroughs

CSL’s Chief Financial Officer David Lamont discusses the company’s latest earnings, its focus on innovation, and also responds to investor concerns about its valuation.

Following the healthcare company’s FY 18 results, CSL’s Chief Financial Officer David Lamont and nabtrade’s Customer Insights Manager Vishal Teckchandani discuss:

  • Data insights on how nabtrade customers are investing in CSL,
  • Why investors should focus on the company's research & development activities,
  • If CSL has an appetite for a stock split, and
  • The CSL-112 trial, which is the largest trial undertaken by CSL for individuals who have suffered a heart attack. 

Note: The article referred to in the video can be viewed here.